The better-than-expected EPS could be seen positively by investors, indicating operational efficiency and cost management. However, the slight miss in sales estimates might temper enthusiasm. Overall, the year-over-year growth in both EPS and sales suggests a positive trajectory for Xenetic Biosciences, potentially leading to a short-term positive impact on the stock price.